AU6510494A - Viable bacteria - Google Patents
Viable bacteriaInfo
- Publication number
- AU6510494A AU6510494A AU65104/94A AU6510494A AU6510494A AU 6510494 A AU6510494 A AU 6510494A AU 65104/94 A AU65104/94 A AU 65104/94A AU 6510494 A AU6510494 A AU 6510494A AU 6510494 A AU6510494 A AU 6510494A
- Authority
- AU
- Australia
- Prior art keywords
- cells
- matrix
- composition
- process according
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000894006 Bacteria Species 0.000 title claims description 12
- 210000004027 cell Anatomy 0.000 claims description 71
- 239000000203 mixture Substances 0.000 claims description 34
- 239000011159 matrix material Substances 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 22
- 230000000813 microbial effect Effects 0.000 claims description 22
- 230000008569 process Effects 0.000 claims description 19
- 150000001875 compounds Chemical class 0.000 claims description 16
- 230000001580 bacterial effect Effects 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 10
- 230000009477 glass transition Effects 0.000 claims description 7
- 150000002772 monosaccharides Chemical class 0.000 claims description 7
- 241000589540 Pseudomonas fluorescens Species 0.000 claims description 6
- 230000006378 damage Effects 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 3
- 230000003466 anti-cipated effect Effects 0.000 claims description 2
- 210000005256 gram-negative cell Anatomy 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 241000588724 Escherichia coli Species 0.000 claims 1
- 230000035899 viability Effects 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 10
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 10
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 10
- 238000004108 freeze drying Methods 0.000 description 10
- 239000000654 additive Substances 0.000 description 8
- 235000000346 sugar Nutrition 0.000 description 7
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000002577 cryoprotective agent Substances 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 235000010378 sodium ascorbate Nutrition 0.000 description 3
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 3
- 229960005055 sodium ascorbate Drugs 0.000 description 3
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 229940072107 ascorbate Drugs 0.000 description 2
- -1 ascorbate compound Chemical class 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 229940049906 glutamate Drugs 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 235000013923 monosodium glutamate Nutrition 0.000 description 2
- 150000002482 oligosaccharides Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 229940073490 sodium glutamate Drugs 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- UYPYRKYUKCHHIB-UHFFFAOYSA-N trimethylamine N-oxide Chemical compound C[N+](C)(C)[O-] UYPYRKYUKCHHIB-UHFFFAOYSA-N 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- 239000007195 tryptone soya broth Substances 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/04—Preserving or maintaining viable microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/04—Enzymes or microbial cells immobilised on or in an organic carrier entrapped within the carrier, e.g. gel or hollow fibres
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Dispersion Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Materials For Medical Uses (AREA)
Description
- l -
VIABLE BACTERIA
This invention relates to a process for the preparation of compositions comprising dried microbial cells in a stasis state, to such compositions and to living cultures prepared therefrom.
Storage of viable cultures is a recognised problem in the art For example, US 3,897,307 discloses d) the use of a combination of an ascorbate compound and a glutamate or aspartate as stabiliser for lactic acid producing bacterial cells and (n) the use of certain sugars, particularly mositol at a concentration of 25mg/ml sample solution, as a cryoprotectant where such bacterial cells are freeze-dried.
Mugnier et al, Applied and Environmental Microbiology, 1985, pp 108-114 discloses the use of polysaccharide gels in combination with certain nutritives, eg C and C compounds, as the matrix for
1-3 6-12 freeze-dried bacterial cells. We have found that gel-forming polysaccharides do not collapse on freeze-drymg.
Redway et al, Cryobiology, 1974, Vol 11, 73-79 examined certain monosaccharides (concentrations up to 150mg/2 ml sample) and related compounds as media for long-term survival of freeze-dried bacteria.
We have now found that where microbial cells are suspended m a certain matrix as hereinafter defined and dried under certain conditions the short-term viability thereof is improved and that where such dried systems are stored and rehydrated under certain conditions as hereinafter defined the long term viability of the microbial cells is improved.
We have further found surprisingly that collapse of the matrix which the microbial cells are suspended does not lead to poor short-term viability.
According to the first aspect of the present invention there is provided a stabilised dried composition comprising microbial cells in a stasis state suspended in a collapsed matrix
By "stabilised" we mean that the degradation of the microbial cells is reduced (which degradation would lead to a loss of recoverable viable cells)
By "stasis state" we mean that the cells are not metabolising, dividing or growing (but are recoverable f subjected to a suitable treatment)
By "recoverable" we mean cells which on exposure to suitable conditions (xe rehydration and source of nutrient) are capable of growth and division.
By "viable cells" we mean cells which on exposure to suitable conditions de rehydration and source of nutrient) are capable of growth and division.
By "collapsed" we mean
I) that the matrix has shrunk and become less porous allowing little penetration of low MW diffusive species into the matrix, eg it absorbs little water vapour on exposure to humid air; and/or
II) the matrix has experienced a temperature above its glass transition temperature (Tg) such that viscous flow thereof has occurred leading to a substantial reduction in surface area/volume ratio and encapsulating the cells m a low porosity protective coating.
According to the second aspect of the present invention there is provided a process for the preparation of a stabilised dried composition comprising microbial cells in a stasis state suspended in a matrix which process comprises the steps of:
A: mixing the microbial cells w th an aqueous composition comprising the material from which the matrix will be derived;
B: drying the mixture under conditions such that viscous flow of the material occurs and the matrix collapses but does not unduly damage the cells .
Preferably the composition prepared n Step B is stored at a temperature below the Tg of the matrix, le the composition has a Tg above its anticipated storage temperature.
Accordingly, the composition prepared in Step B is preferably dried further, so-called "secondary drying", to increase the Tg of the matrix such that the composition is stabilised to a broader range of storage conditions, le it can be stored at a higher temperature.
The microbial cells of which the stabilised dried composition according to the present invention is comprised are preferably bacterial cells. However, we do not exclude the possibility that alternative microbial cells may be used, eg fungi, yeast, etc. Where the microbial cells are bacterial cells they are preferably Gram-negative bacterial cells although we do not exclude the possibility that they may be cells of a
Gram-positive bacteria As examples of such Gram-negative cells may be mentioned inter alia Pseudomonas fluorescens, Escherich a coll and rhizosphere-assoc ated bacteria.
The concentration of the microbial cells in the mixture prepared in
4 Step A of the process according to the present invention is between 10 /ml and 10 /ml and preferably is between 10 /ml and 10 /ml.
The material which is mixed with the microbial cells m Step A of the process according to the present invention is a polyhydroxy compound, eg a polyol such as mannitol, mositol, sorbitol, galactitol, or preferably a carbohydrate, more preferably a sacchande.
Where the material is a sacchande it may be a di-sacchande, a tri-saccharide, an oligo-saccharide, or preferably a monosaccharide. As examples of mono-saccharides may be mentioned into al a hexoses, eg rhamnose, xylose, fructose, glucose, mannose and galactose. As examples of disaccharides may be mentioned inter alia maltose, lactose, trehalose and sucrose. As an example of a tπsaccharide may be mentioned raff ose. As examples of oligosaccharides may be mentioned maltodextrms .
The concentration of the polyhydroxy compound used in the mixture in Step A of the process according to the present invention is between lOmg/10 and lOOOmg/10 cells and preferably between 200mg/10 cells and 400mg/10 cells. The skilled person will be able to find by simple experiment the concentrations from which a collapsed matrix can be prepared for a particular polyhydroxy compound. For example, we have found that mositol has an optimum concentration at about 45 mg/ml, it causes massive cell damage above 60 mg/ml and does not collapse at below about 25 mg/ml.
Certain of the polyhydroxy compounds exhibit protective properties over a wide range of concentrations, whereas certain others above a critical concentration, which appears to be related to the solubility of the polyhydroxy compound m the aqueous medium, exhibit a detrimental effect.
The present invention is further illustrated by reference to the accompanying drawings which illustrate, by way of example only, compositions according to the present invention
In the drawings.
Figure 1 illustrates in the form of a graph the variation of viability of Pseudomonas fluorescens with mositol (additive) concentration when
freeze-dried from water or 0.04M MgSO The vertical axis represents
9 8 viability in parts per billion de 1E+09=10 ppb, 1E+08=10 ppb, etc) and the horizontal axis represents the concentration of the additive n milligrams per sample The black squares (9) on the graph plot mositol in magnesium sulphate and the circles (o) plot mositol in water.
Figures 2 to 7 illustrate in the form of graphs the variation of viability of freeze-dried Pseudomonas fluorescens w th monosaccharide concentration for a range of monosacchaπdes. The vertical axis represents viability in parts per billion, in numbers of billions de 1E+0=1 billion,
5E-1=0.5 billion, 2E-1=0.2 billion, etc) and the horizontal axis represents the sugar concentration in milligrams per sample. The monosaccharides illustrated are:
Figure 2 galactose Figure 5 xylose
Figure 3 fructose Figure 6 rhamnose
Figure 4 glucose Figure 7 mannose
Figure 8 illustrates m the form of a graph the variation of cell death rate (k ) with Tg of the matrix and the variation of Tg with relative humidity The left-hand vertical axis represents k , the right-hand vertical axis represents Tg (°C) and the horizontal axis represents relative humidity (%) . The black squares (•) on the graph connected by a solid line plot the cell death rate constant (k ) and the lozenges connected by a broken line plot the glass transition temperature (Tg) .
In the drawings, viability is expressed as the number of viable
9 bacteria per 10 viable bacteria in the original suspension, le it represents the number of bacteria which survive from each one billion bacteria which were viable initially It is represented as the parts per
9 8 billion viability (ppb) , le 10 ppb is equivalent to 100% survival and 10 is equivalent to 10% survival, etc
From Figure 1 it can be seen that at low mositol concentrations the viability of the cells s maintained whereas at higher concentrations, eg greater than lOOmg/sample (equivalent to 50mg/ml) , cell viability rapidly decreases .
From Figures 2 to 7 it can be seen that certain monosaccharides protect the cells from damage at low concentrations, eg less than 10 mg/sample (equivalent to 5mg/ml) and that protection is substantially maintained at high concentrations, eg about 400 mg/sample (equivalent to 130mg/ml) .
From Figure 8 it can be seen that where the Tg drops below the storage temperature (represented by the top horizontal line at 21-22°C) , the rate of cell death (k ) increases significantly, illustrating the importance of maintaining a glassy state during storage.
The concentration at which the material is effective, ie it collapses without unduly damaging the cells, is dependent on a variety of factors, including inter alia: the volume fraction of the cells in the suspension in Step A; the inherent glass transition temperature of the polyhydroxy compound; the variation in glass transition temperature of the matrix as a function of water concentration therein; and the temperature to which the matrix is exposed during and after freeze-drying.
It will be appreciated that the polyhydroxy compound may act as (i) a cryo-protectant at low temperature, particularly against damage by ice-particles during freeze-drying; and /or (ii) a lyo-protectant protecting against damage due to loss of water during drying and/or storing; and /or (iii) a nutrient source during recovery of the cell.
The microbial cells for use in the process of the present invention may be grown in conventional growth media, eg nutrient broth or tryptone soya broth. They may be harvested at any convenient phase of growth, preferably at early stationary phase.
For example, a culture is grown in or on a suitable medium, eg liquid or solid plates, to give a desired cell concentration. The cells are isolated, typically by centrifugation. They are resuspended in an aqueous composition comprising the material which will form the matrix and optionally certain other additives as mentioned hereinafter.
Preferably, the microbial cells used in the process of the present invention are isolated from the growth medium, resuspended in a solution comprising polyhydroxy compound, suitable additives, etc and dried. However, we do not exclude the possibility that the polyhydroxy compound and suitable additives, etc are added to the cells in the growth medium and the resulting mixture dried.
Where the microbial cells are resuspended, they are resuspended in a suitable aqueous medium, eg aqueous MgSO solution, or preferably water, containing the polyhydroxy compound.
The drying in Step B of the process according to the present invention may be carried out by, for example, evaporation, vacuum-drying, spray-drying, air-drying or preferably freeze-drying.
As hereinbefore defined it is essential to achieve viscous flow during at least the drying step, Step B, or any subsequent step.
Typically the water content of the dried composition prepared in Step B is less than 15% w/w.
Where the drying in Step B comprises freeze-drying the composition typically contains one or more suitable additives. As examples of suitable additives may be mentioned inter alia cryo-protectants, for example sugars or polymeric species, eg polyvinylalcohol, polyvinylpyrrolidone; lyo-protectants, for example sugars or polymeric species, eg polyvinyl alcohol, polyethylene glycol; or preferably anti-oxidants or so-called potentiators, eg ascorbate or glutamate. We do not exclude the possibility that other additives may be present, for example, so-called bulking agents, for example crystallising sugars, eg mannitol, and osmo-regulants, eg betaine, urea/trimethylamine-N-oxide, proline, sarcosine.
The present invention is further illustrated by reference to the following Examples.
EXAMPLES 1-6
These Examples illustrate compositions according to the present invention wherein the matrix comprises rhamnose.
Pseudomonas fluorescens was cultured in standard media (double strength nutrient broth) and harvested in early stationary phase by centrifugation. The cell concentrate was resuspended in sterile water and a sufficient volume of an autoclave-sterilised, concentrated rhamnose solution was added to give approximately 200 aliquots of a final concentration of 200 mg of sugar to 2x10 cells in a total volume of 4ml water in 5ml capacity freeze-drying vials.
The vials were loaded onto the temperature-controlled shelves of a freeze-drying apparatus and the shelf-temperature was driven to -30°C, freezing the contents of the vials and lowering their temperatures to -28°C to -30°C, over a two hour period. Vacuum was applied and primary drying
was carried out over a period of 48 hours. The shelf temperature was raised to 0°C and secondary drying was allowed to occur for 24 hours. The vials were brought to room temperature and sealed under vacuum before removal from the freeze-drier.
The vials were stored at 4°C in vacuo (Example 1) or in humidity controlled air at 21°C (Examples 2-6) .
The samples were rehydrated in sterile water and viable bacterial cell numbers were determined by serial dilution in water followed by plating onto King's B growth medium. The number of colony-forming units (cfu) on the highest dilution plates was used to calculate the number of bacterial cells per unit volume which survived the freeze-drying and storage conditions .
Immediately after freeze-drying the viability of the cells was
8 3x10 ppb.
The results from bacteria stored at 4°C in vacuo are shown in Table 1.
TABLE 1
Example
Viability (ppb) No. after storage for (weeks)
3 50
1 ND 5x10 CT1 0
ND: not determined
CT1 is a Comparative Test with no rhamnose present.
From Table 1 it can be seen that the presence of a rhamnose matrix improves the viability of the bacteria substantially.
The results from bacteria stored at 21°C in controlled humidity chambers are shown in Table 2.
TABLE 2
Example Rel Viability (ppb) No. humidity after storage for (days)
(RH%) 13 27 34
7
2 1 8xl07 3X10 4X10
7
3 4 3x10 7x10 2x10
7
4 9 9x10 5x10 4x10
7 6
5 23 4X10 4X10 8x10
7
6 44 3x10 1X10 3X105
CT2 1 ιo3
CT2 is a Comparative Example with no rhamnose present.
From Table 2 it can be seen that the presence of a sugar substantially increases the viability even at low RH, ie Ex 2 compared with CT2.
EXAMPLES 7-10
These Examples illustrate compositions according to the present invention wherein the matrix comprises rhamnose and magnesium sulphate.
The procedure of Examples 1-6 was repeated except that the cell concentrate was resuspended in 0.04M magnesium sulphate instead of sterile water and rhamnose solution was then added. p
The viability of the cells immediately after freeze-drying was 5x10 . The freeze-dried cells were stored at the temperatures and for the periods of time shown in Table 3.
TABLE 3
Example Storage Viability (ppb) after days No. temp (°C) 50 100 175 365
8 8 8
7 -20 5x10 5x10 5x10 5x10
8 8 8
8 4 2x10 2x10 1x10
8 7
9 15 1x10 5x10
7
10 20 2x10
It can be seen from Table 3 that the formulation provides substantial protection over a range of temperatures.
EXAMPLES 11-15
These Examples illustrate compositions according to the present invention wherein sodium ascorbate and sodium glutamate are present in the matrix.
The procedure of Examples 1-6 was repeated except that concentrated aqueous solutions of sodium ascorbate and sodium glutamate were added to the resuspended cells in water and rhamnose.
8 The viability of the cells immediately after freeze-drying was 2x10 ppb.
The samples were stored in humid air at 21°C.
TABLE 4
Example Relative Viability (ppb) Tg No. humidity after storage for (days) °C (RH%) 34 128
8 8
11 0 1X10 1X10 25
12 14 24
7
13 30 4X10 14
7 6
14 40 9x10 5X10 12
7 j 15 53 3x10 3x10 8 i
From Examples 11 and 12 in Table 4 it can be seen that storing the dried cells at temperatures below the Tg of the matrix stabilises the cells for long periods .
The results indicate that the combination of collapsed matrix in a glassy state and the presence of an anti-oxidant provides a matrix which can stabilise the viable cells for long periods of time under relatively harsh environments .
EXAMPLE 16
A 4g pellet of Pseudomonas fluorescens cells, separated from culture media by centrifugation and containing 5.10 viable cells, was mixed with 14g of a commercial grade of maltodextrin (Glucidex IT19) and 1.6g of sodium ascorbate and the material, initially at room temperature, dried
under reduced pressure, in which the evaporated water condensed onto an ice trap maintained at -50°C.
Drying was terminated after approximately 18 hours, at which time the vacuum was of the order of 1 mbar.
Samples rehydrated into pure water and plated onto Nutrient agar typically showed 50-90% recovery of viable cells.
Materials prepared by this method appear as collapsed amorphous matrices with glass transitions exceeding 20°C (when samples were exposed to standard laboratory relative humidities) .
Claims (13)
1. A stabilised dried composition comprising microbial cells in a stasis state suspended in a collapsed matrix.
2. A composition according to claim 1 in which the microbial cells are bacterial cells.
3. A composition according to claim 2 in which the bacterial cells are Gram-negative bacterial cells.
4. A composition according to claim 3 in which the Gram-negative cells are Pseudomonas fluorescens, Escherichia coli or rhizosphere-associated bacteria.
5. A process for the preparation of a stabilised dried composition comprising microbial cells in a stasis state suspended in a matrix which process comprises the steps of:
A: mixing the microbial cells with an aqueous composition comprising the material from which the matrix will be derived;
B: drying the mixture under conditions such that viscous flow of the material occurs and the matrix collapses but does not unduly damage the cells.
6. A process according to claim 5 in which the composition prepared in step B is dried further to increase the glass transition temperature of the matrix such that the composition is stabilised to a broader range of storage conditions.
7. A process according to claim 5 in which the concentration of the
4 microbial cells in the mixture prepared in Step A is between 10 /ml
13 , , and 10 /ml.
8. A process according to claim 7 in which the concentration of the cells is between 10 /ml and 10 /ml.
9. A process according to claim 5 in which the material which is mixed with the microbial cells in Step A of the process is a polyhydroxy compound.
10. A process according to claim 9 in which the polyhydroxy compound is a monosaccharide.
11. A process according to claim 9 in which the concentration of the polyhydroxy compound used in the mixture in Step A is between lOmg/10 and lOOOmg/10 cells.
12. A process according to claim 11 in which the concentration of the polyhydroxy compound is between 200mg/10 cells and 400mg/10 cells.
13. A composition prepared according to claim 5 which has a glass transition temperature above its anticipated storage temperature.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9308734 | 1993-04-28 | ||
GB939308734A GB9308734D0 (en) | 1993-04-28 | 1993-04-28 | Viable bacteria |
PCT/GB1994/000811 WO1994025564A1 (en) | 1993-04-28 | 1994-04-18 | Viable bacteria |
Publications (2)
Publication Number | Publication Date |
---|---|
AU6510494A true AU6510494A (en) | 1994-11-21 |
AU684072B2 AU684072B2 (en) | 1997-12-04 |
Family
ID=10734585
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU65104/94A Ceased AU684072B2 (en) | 1993-04-28 | 1994-04-18 | Viable bacteria |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP0696316A1 (en) |
JP (1) | JPH08509374A (en) |
KR (1) | KR960701986A (en) |
CN (1) | CN1121731A (en) |
AU (1) | AU684072B2 (en) |
BG (1) | BG100105A (en) |
BR (1) | BR9406488A (en) |
CA (1) | CA2161220A1 (en) |
CZ (1) | CZ280595A3 (en) |
GB (2) | GB9308734D0 (en) |
HU (1) | HUT72846A (en) |
NZ (1) | NZ263867A (en) |
PL (1) | PL311297A1 (en) |
SK (1) | SK134695A3 (en) |
WO (1) | WO1994025564A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9619893D0 (en) * | 1996-09-24 | 1996-11-06 | Zeneca Ltd | Novel composition |
EP1032647B1 (en) * | 1997-11-26 | 2006-03-29 | Universal Preservation Technologies, Inc. | Preservation of sensitive biological samples by vitrification |
DE19819475A1 (en) * | 1998-04-30 | 1999-11-04 | Basf Ag | Dry microorganism cultures and methods for their production |
KR101088073B1 (en) | 2010-10-16 | 2011-12-01 | 주식회사 샤인 | Battery having an electrode structure including metal long fibers and method for manufacturing same |
DK2654417T3 (en) | 2010-12-23 | 2018-10-29 | Dupont Nutrition Biosci Aps | COLD PROTECTIVE COMPOSITIONS AND APPLICATIONS THEREOF |
CN102408993B (en) * | 2011-11-23 | 2013-06-19 | 陕西农产品加工技术研究院 | Bifidobacterium bifidum anti-freeze culture medium and application method thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3614M (en) * | 1965-07-01 | 1965-10-18 | Carlo Giuseppe Sigurta | Anhydrous, stable compositions of lactobacilli, yeast-streptococci and some other species of bacilli and their preparation process. |
AT275040B (en) * | 1967-04-11 | 1969-10-10 | Werner Buehrdel | Process to extend the viability and to facilitate the therapeutic applicability of freeze-dried bacterial cultures |
AU1087176A (en) * | 1975-03-03 | 1977-08-11 | Miles Lab | Water soluble microbial composition |
EP0265253A3 (en) * | 1986-10-24 | 1990-01-10 | Kingston Technologies, Inc. | Stabilized dispersed enzyme |
GB8713601D0 (en) * | 1987-06-10 | 1987-07-15 | Unilever Plc | Fermentation |
DE3854472T2 (en) * | 1988-06-17 | 1996-02-29 | Cominco Fertilizers Ltd | Maintenance of the viability of microorganisms for use in microbial inoculants. |
GB8903593D0 (en) * | 1989-02-16 | 1989-04-05 | Pafra Ltd | Storage of materials |
GB9002003D0 (en) * | 1990-01-29 | 1990-03-28 | Ici Plc | Stabilized cultures of microorganisms |
FR2676751B1 (en) * | 1991-05-24 | 1993-09-17 | Lacto Labo Sa | COMPOSITION SUITABLE FOR THE CONSERVATION OF ACTIVE FUNGAL SPORES. |
AU659645B2 (en) * | 1991-06-26 | 1995-05-25 | Inhale Therapeutic Systems | Storage of materials |
-
1993
- 1993-04-28 GB GB939308734A patent/GB9308734D0/en active Pending
-
1994
- 1994-03-31 GB GB9406552A patent/GB9406552D0/en active Pending
- 1994-04-18 NZ NZ263867A patent/NZ263867A/en unknown
- 1994-04-18 BR BR9406488A patent/BR9406488A/en not_active Application Discontinuation
- 1994-04-18 CN CN94191905A patent/CN1121731A/en active Pending
- 1994-04-18 AU AU65104/94A patent/AU684072B2/en not_active Ceased
- 1994-04-18 EP EP94912638A patent/EP0696316A1/en not_active Withdrawn
- 1994-04-18 PL PL94311297A patent/PL311297A1/en unknown
- 1994-04-18 CZ CZ952805A patent/CZ280595A3/en unknown
- 1994-04-18 JP JP6523994A patent/JPH08509374A/en active Pending
- 1994-04-18 KR KR1019950704675A patent/KR960701986A/en not_active Abandoned
- 1994-04-18 WO PCT/GB1994/000811 patent/WO1994025564A1/en not_active Application Discontinuation
- 1994-04-18 CA CA002161220A patent/CA2161220A1/en not_active Abandoned
- 1994-04-18 SK SK1346-95A patent/SK134695A3/en unknown
- 1994-04-18 HU HU9503064A patent/HUT72846A/en unknown
-
1995
- 1995-10-30 BG BG100105A patent/BG100105A/en unknown
Also Published As
Publication number | Publication date |
---|---|
JPH08509374A (en) | 1996-10-08 |
CA2161220A1 (en) | 1994-11-10 |
EP0696316A1 (en) | 1996-02-14 |
SK134695A3 (en) | 1996-06-05 |
WO1994025564A1 (en) | 1994-11-10 |
HUT72846A (en) | 1996-05-28 |
BG100105A (en) | 1996-12-31 |
GB9308734D0 (en) | 1993-06-09 |
KR960701986A (en) | 1996-03-28 |
CZ280595A3 (en) | 1996-02-14 |
HU9503064D0 (en) | 1995-12-28 |
GB9406552D0 (en) | 1994-05-25 |
PL311297A1 (en) | 1996-02-05 |
BR9406488A (en) | 1996-01-09 |
AU684072B2 (en) | 1997-12-04 |
CN1121731A (en) | 1996-05-01 |
NZ263867A (en) | 1997-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1303184B1 (en) | Preservation and storage medium for biological materials | |
US5089407A (en) | Encapsulation of biological material in non-ionic polymer beads | |
CA2218929C (en) | Compositions in glassy phase, stabilised by a sugar | |
US5098893A (en) | Storage of materials | |
AU2001268057A1 (en) | Preservation and storage medium for biological materials | |
US20040110267A1 (en) | Room temperature stable competent cells | |
Tan et al. | Freeze-drying of fungi: influence of composition and glass transition temperature of the protectant | |
AU684072B2 (en) | Viable bacteria | |
CA1336765C (en) | Method for encapsulating biological material and composition produced by such method | |
CA1300538C (en) | Maintenance of the viability of microorganisms for use in microbial inoculants | |
KR101811530B1 (en) | Development of Hansenispora uvarum starter by using Ca-alginate bead after air-blast drying | |
CN110724639A (en) | Marine luminous bacteria freeze-dried preparation and preparation method thereof | |
Yoshida et al. | Immobilization of enzymes by radiation-induced polymerization of glass-forming monomers: 2. Effects of cooling rate and solvent on porosity and activity of immobilized enzymes | |
CN1286725A (en) | Vitrification quality guarantee method for sensitive biological sample | |
AU613079B2 (en) | Maintenance of the viability of microorganisms for use in microbial inoculants | |
KR100396374B1 (en) | Method for manufacturing freeze-dried mycelium having excellent storageability and composition of freeze-drying protection agent therefor | |
KR101820240B1 (en) | Development of Saccharomyces cerevisiae starter by using Ca-alginate bead after air-blast drying | |
EP0929660A1 (en) | Novel composition | |
JP2000139447A (en) | Freeze-drying of microorganism capable of fermentatively decomposing saccharides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |